Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

Merck agreed to acquire biotech Terns Pharma in a deal valued at up to $6.7 billion to bolster its cancer drug pipeline. The deal is a strategic defensive move ahead of looming patent loss for Keytruda, aiming to replenish future oncology revenue streams. Expect this to be viewed positively for Merck's late-stage pipeline prospects while increasing near-term capital spend and integration risk.

Analysis

Merck agreed to acquire biotech Terns Pharma in a deal valued at up to $6.7 billion to bolster its cancer drug pipeline. The deal is a strategic defensive move ahead of looming patent loss for Keytruda, aiming to replenish future oncology revenue streams. Expect this to be viewed positively for Merck's late-stage pipeline prospects while increasing near-term capital spend and integration risk.